Etanercept biosimilar has comparable pharmacokinetics to Enbrel

Biosimilars/Research | Posted 15/11/2013 post-comment0 Post your comment

An etanercept biosimilar (CHS-0214) from fledgling biotech company Coherus Biosciences (Coherus) has shown comparable pharmacokinetics in a pivotal clinical study.

Pharmacokinetics 1 V13K15

Coherus announced on 28 October 2013 that its etanercept biosimilar, CHS-0214, had met the primary endpoint of clinical pharmacokinetic similarity to the originator biological Enbrel (etanercept) in a confirmatory clinical study in healthy subjects. This trial meets European Union, Japanese and US regulatory requirements for clinical pharmacokinetic similarity, according to Coherus.

The two-period, crossover study met the study acceptance criteria for similarity in clinical pharmacokinetics on all three required endpoints: maximum serum concentration (Cmax), area under the time-concentration curve from first to last time point measured (AUC0-t) and area under the time-concentration curve from first time point to infinity (AUC0-∞). The geometric mean ratios were 98% for CHS-0214 compared to Enbrel and were fully within the pre-specified regulatory bounds for the 90% confidence interval for Cmax, AUC0-t, and AUC0-∞.

Coherus made an agreement with Daiichi Sankyo in May 2012 to develop and commercialize biosimilars of etanercept and rituximab in certain Asian countries including Japan [1].  In September 2013 Coherus made an exclusive collaboration agreement with Baxter International to develop and commercialize an etanercept biosimilar for Brazil, Canada, Europe and certain other markets [2].

Coherus intends to pursue the next stage of development – a second clinical study, which is required for filing a biosimilar marketing application across most regulatory jurisdictions – ‘in the very near future’. This will be carried out as part of its collaboration with Daiichi Sankyo and Baxter.

Amgen’s sales of Enbrel in 2012 were US$4.2 billion making it a lucrative target for biosimilars manufacturers. Coherus joins an ever-growing list of companies focusing on developing biosimilars of Amgen’s Enbrel, with Biocon/Mylan, Celltrion, Mycenax, Samsung/Biogen Idec and Sandoz all having biosimilar versions of etanercept in clinical development. India-based generics’ manufacturer Cipla also launched its ‘similar biologic’ product Etacept in April 2013, the first ‘similar biologic’ of etanercept in India [3]. A ‘similar biotherapeutic product’ Etanar has also been approved in Colombia [4].

Editor’s comment
It should be noted that ‘similar biologics’ approved in India and ‘similar biotherapeutic products’ approved in Colombia might not have been authorized following as strict a regulatory process as is required for approval of biosimilars in the EU. EMA regulatory requirements ensure the same high standards of quality, safety and efficacy for biosimilars as for originator biologicals, and also include a rigorous comparability exercise with the reference product.

Related articles

Trials to start for biosimilar infliximab and etanercept

Sandoz to start phase III etanercept trial


1.  GaBI Online - Generics and Biosimilars Initiative. Daiichi Sankyo and Coherus Biosciences make biosimilars deal []. Mol, Belgium: Pro Pharma Communications International; [cited 2013 Nov 15]. Available from:

2.  GaBI Online - Generics and Biosimilars Initiative. Baxter and Coherus to collaborate on biosimilars []. Mol, Belgium: Pro Pharma Communications International; [cited 2013 Nov 15]. Available from:    

3.  GaBI Online - Generics and Biosimilars Initiative. Cipla launches first etanercept ‘similar biologic’ in India []. Mol, Belgium: Pro Pharma Communications International; [cited 2013 Nov 15]. Available from:

4.  GaBI Online - Generics and Biosimilars Initiative. Similar biotherapeutic products approved and marketed in Latin America []. Mol, Belgium: Pro Pharma Communications International; [cited 2013 Nov 15]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2013 Pro Pharma Communications International. All Rights Reserved.

Source: Amgen, Coherus

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010